At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
LTI-03 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects With IPF
In Brief
A Phase 1 clinical trial evaluating LTI-03 and Placebo for Idiopathic Pulmonary Fibrosis. Completed, enrolled 24 participants across 7 sites in 3 countries.
Detailed Summary
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesGermany, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartJul 2023
First PostedJul 2023
Primary CompletionSep 2024
TodayJul 2026
First PostedJul 20, 2023
Enrollment StartJul 6, 2023
Primary CompletionSep 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 2.9 years ago
Interventions
LTI-03drug
Caveolin-1-Scaffolding-Protein-Derived Peptide
Placebodrug
Matching placebo